A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
Spatial Analysis of Genomic Signatures on Colorectal Cancer Pathogenesis Using the NanoString GeoMx® Digital Spatial Profiler
Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies
Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay
Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay